Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2022

View Archived Issues

Targeting NMNAT2 confers neuroprotection in glaucoma

Hangzhou Zhongmei Huadong Pharmaceutical divulges GLP-1 receptor agonists

Universite du Luxembourg discloses new PDE6D inhibitors

Ranok Therapeutics presents new CHAMPs for cancer

Beijing Jacobio Pharmaceuticals identifies new glutaminase inhibitors

Shanghai De Novo Pharmatech synthesizes new ATR kinase inhibitors

Discovery of potent and orally bioavailable CSNK1A1 inhibitors

Clec9A-M2e construct may be a step towards a universal influenza vaccine

ANGPTL7 as a novel therapeutic target for glaucoma

TBK1 inhibition is neuroprotective in optic neuropathies

iBio presents preclinical data on monoclonal antibody candidate IBIO-101 for solid tumors

Ichnos selects trispecific antibody ISB-2001 for development in multiple myeloma

Aqilion advances program for chronic inflammatory bowel disease

Researchers develop a murine model of TEK Schlemm's canal conditional knockdown glaucoma

Comparative study focuses lens of human reproductive aging

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...